Field Name	Field Description
Prior Authorization Group Description	**Synagis (palivizumab)**
Drugs	Synagis (palivvizumab)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	N/A
Required Medical Information	See "other criteria"
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	A maximum of 5 doses may be approved within the Respiratory Syncytial Virus (RSV) season. Requests for additional doses will be reviewed on a case-by case basis based on CDC surveillance reports, state/local health department recommendations, and other current medical literature.
Other Criteria	Infants less than 1 year of age at the onset of the respiratory syncytial virus (RSV) season (which typically starts October 1st, but may vary seasonally) **AND** have one of the following indications: • Born at less than 29 weeks, 0 days gestation • Born at less than 32 weeks, 0 days gestation AND had chronic lung disease of prematurity defined as greater than 21% oxygen for at least 28 days after birth • Born at any gestational age with hemodynamically significant heart disease including: o Cyanotic heart disease in consultation with a pediatric cardiologist o Acyanotic Heart disease with one of the following: ▪ On heart failure medication and expected to require cardiac surgical procedure ▪ Moderate to severe pulmonary hypertension • Cystic fibrosis with clinical evidence of chronic lung disease (CLD) and/or nutritional compromise in the first year of life • Born at any gestational age with pulmonary abnormality or neuromuscular disease that impairs the ability to clear secretions from the lower airway Infants less than 2 years of age at the onset of the RSV season (which typically starts October 1st, but may vary seasonally) **AND** have one of the following indications: • Born at less than 32 weeks, 0 days AND had a diagnosis of chronic lung disease of prematurity at birth as defined above

Revision/Review Date: 7/2023	**AND** had continued need for one of the following respiratory interventions in the 6 months preceding RSV season: Chronic steroids, chronic diuretics, supplemental oxygen • Cystic fibrosis with manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest radiography or chest computed tomography that persist when stable) or weight for length less than the 10th percentile • Born at any gestational age and will be profoundly immunocompromised during the RSV season, including: o Solid organ or hematopoietic stem cell transplant recipient o Chemotherapy recipient • Born at any gestational age and receiving a cardiac transplant **Medical Director/clinical reviewer may override criteria when, in his/her professional judgement, the requested item is medically necessary.**

PerformRx recommends approving the Synagis prior authorization criteria with no changes for ACOH.